Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

CRBU

Caribou Biosciences Inc

Feb 13 • 04:00PM ET

1.58

+0.06 3.95 %

Healthcare • Biotechnology • USA • NASD

Peers: EDIT CRSP BEAM NTLA VRTX QURE BLUE PSTX SGMO DTIL

| Held by: VTI VXF IBB SCHA NXTE DFAS AVSC DFAC XDNA SCHB

Index	-	P/E	-	EPS (ttm)	-1.70	Insider Own	11.44%	Shs Outstand	93.47M	Perf Week	0.64%
Market Cap	147.68M	Forward P/E	-	EPS next Y	-1.34	Insider Trans	0.00%	Shs Float	82.78M	Perf Month	-1.86%
Enterprise Value	25.88M	PEG	-	EPS next Q	-0.31	Inst Own	38.14%	Short Float	9.10%	Perf Quarter	-30.09%
Income	-157.13M	P/S	15.90	EPS this Y	3.79%	Inst Trans	-3.30%	Short Ratio	6.90	Perf Half Y	-21.00%
Sales	9.29M	P/B	1.04	EPS next Y	15.35%	ROA	-58.27%	Short Interest	7.53M	Perf YTD	-0.63%
Book/sh	1.52	P/C	1.00	EPS next 5Y	7.32%	ROE	-74.28%	52W High	3.54 -55.30%	Perf Year	20.61%
Cash/sh	1.58	P/FCF	-	EPS past 3/5Y	-14.13% -33.41%	ROIC	-95.45%	52W Low	0.66 139.39%	Perf 3Y	-76.52%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	1.36% 11.54%	Gross Margin	55.38%	Volatility	7.24% 7.43%	Perf 5Y	-
Dividend TTM	-	EV/Sales	2.79	EPS Y/Y TTM	-2.72%	Oper. Margin	-1577.36%	ATR (14)	0.11	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.54	Sales Y/Y TTM	-19.00%	Profit Margin	-1690.45%	RSI (14)	50.16	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.54	EPS Q/Q	22.98%	SMA20	3.40%	Beta	2.58	Target Price	11.12
Payout	-	Debt/Eq	0.18	Sales Q/Q	8.60%	SMA50	-3.55%	Rel Volume	1.39	Prev Close	1.52
Employees	147	LT Debt/Eq	0.16	Earnings	Nov 12 AMC	SMA200	-8.89%	Avg Volume	1.09M	Price	1.58
IPO	Jul 23, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	15.25% -3.24%	Trades		Volume	1,515,261	Change	3.95%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-03-24	Downgrade	Evercore ISI	Outperform → In-line	$13 → $3
Nov-08-23	Initiated	Cantor Fitzgerald	Neutral
Oct-31-23	Initiated	Evercore ISI	Outperform	$13
Jul-11-23	Initiated	Truist	Buy	$23
Feb-18-22	Initiated	RBC Capital Mkts	Outperform	$22
Dec-01-21	Initiated	Oppenheimer	Outperform	$36
Nov-30-21	Initiated	H.C. Wainwright	Buy	$28
Nov-15-21	Upgrade	Citigroup	Neutral → Buy	$27
Aug-17-21	Initiated	SVB Leerink	Outperform	$32
Aug-17-21	Initiated	Citigroup	Neutral	$27
Aug-17-21	Initiated	BofA Securities	Buy	$30

Show Previous Ratings

Feb-12-26 04:05PM	Caribou Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-10-26 09:40AM	Is Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-04-26 08:00AM	Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire)
Jan-13-26 12:00PM	Caribou Biosciences (CRBU) Upgraded to Buy: Here's Why (Zacks)
Dec-01-25 04:05PM	Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025 (GlobeNewswire) -8.76%
05:30PM	Loading…
Nov-12-25 05:30PM	Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -12.17%
04:05PM	Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-10-25 08:20AM	Septerna, Inc. (SEPN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-03-25 05:15PM	Caribou Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire) -10.70%
07:00AM	Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma (GlobeNewswire)
07:00AM	Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies (GlobeNewswire)
06:54AM	Caribou results suggest renewed promise for off-the-shelf cancer cell therapy (BioPharma Dive)
Nov-02-25 04:00PM	Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma (GlobeNewswire)
Aug-25-25 04:05PM	Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference (GlobeNewswire) +6.38%
Aug-12-25 04:05PM	Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +8.94%
07:20AM	Loading…
Jul-31-25 07:20AM	Biogen Inc. (BIIB) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
May-28-25 04:00PM	Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-13-25 12:00PM	Caribou Biosciences (CRBU) Upgraded to Buy: Here's What You Should Know (Zacks)
May-08-25 05:25PM	Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-06-25 04:00PM	Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference (GlobeNewswire) -12.16%
May-01-25 10:01AM	Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know (Zacks) -5.77%
Apr-29-25 10:01AM	Will Caribou Biosciences, Inc. (CRBU) Report Negative Q1 Earnings? What You Should Know (Zacks) +10.44%
Apr-25-25 07:50AM	Caribou cuts pipeline and workforce to focus on lead CAR-T programmes (Pharmaceutical Technology) -11.30%
05:00AM	Caribou, in reversal, scraps autoimmune cell therapy and cuts staff (BioPharma Dive)
Apr-24-25 04:15PM	Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs (GlobeNewswire)
08:10AM	Bristol Myers Squibb (BMY) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
Mar-10-25 05:15PM	Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-18-25 04:05PM	Caribou Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.19%
05:45AM	Loading…
05:45AM	Shareholders of Caribou Biosciences, Inc. Should Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your Rights - CRBU (PR Newswire)
Feb-07-25 05:45AM	Caribou Biosciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your Rights - CRBU (PR Newswire)
Jan-31-25 05:45AM	Caribou Biosciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - CRBU (PR Newswire) +9.16%
Jan-24-25 05:45AM	Caribou Biosciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your Rights - CRBU (PR Newswire)
Jan-17-25 05:45AM	Caribou Biosciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your Rights - CRBU (PR Newswire)
Jan-14-25 05:45AM	Investors in Caribou Biosciences, Inc. Should Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your Rights - CRBU (PR Newswire)
Jan-12-25 07:05PM	Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025 (GlobeNewswire)
Jan-07-25 04:00PM	Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -8.02%
Jan-02-25 08:00AM	Caribou Biosciences Appoints Sri Ryali as Chief Financial Officer (GlobeNewswire) +5.66%
Dec-30-24 03:01PM	Why Is Caribou Biosciences Inc. (CRBU) Among the Top CRISPR Stocks to Invest In? (Insider Monkey)
Dec-16-24 09:55AM	Caribou Biosciences (CRBU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-20-24 04:00PM	Caribou Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-06-24 06:05PM	Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +7.42%
04:05PM	Caribou Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-31-24 03:53AM	Is Caribou Biosciences (CRBU) a Promising Gene Editing Stock? (Insider Monkey)
Oct-17-24 03:06PM	STATE STREET CORP's Strategic Acquisition in Caribou Biosciences Inc (GuruFocus.com) -5.83%
Sep-25-24 09:00AM	Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024 (GlobeNewswire)
Sep-03-24 08:00AM	Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML (GlobeNewswire) -8.33%
Aug-26-24 04:00PM	Caribou Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-12-24 08:00AM	Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer (GlobeNewswire)
Aug-06-24 06:50PM	Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
10:00AM	Caribou Biosciences, Inc. (CRBU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks)
Jul-17-24 07:45AM	Caribou lays off staff; Roche walks away from Relay (BioPharma Dive)
Jul-09-24 08:00AM	Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board (GlobeNewswire)
Jun-02-24 07:00PM	Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-30-24 04:01PM	Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences (GlobeNewswire)
May-12-24 04:00PM	3 Underappreciated Stocks That Could 10x in 10 Years (InvestorPlace)
May-09-24 05:23AM	Truist Adjusts Price Target on Caribou Biosciences to $19 From $21, Maintains Buy Rating (MT Newswires)
May-07-24 10:55PM	CRBU Stock Earnings: Caribou Biosciences Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -6.17%
05:25PM	Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-01-24 04:05PM	Caribou Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-27-24 06:00AM	Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm (GlobeNewswire)
Apr-24-24 10:00AM	Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-15-24 09:00AM	Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) (GlobeNewswire)
Apr-04-24 04:00PM	Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus (GlobeNewswire)
Mar-14-24 12:00PM	All You Need to Know About Caribou Biosciences, Inc. (CRBU) Rating Upgrade to Buy (Zacks)
Mar-13-24 03:32PM	11 Oversold NASDAQ Stocks To Buy Right Now (Insider Monkey) +11.55%
Mar-12-24 12:37PM	Why Caribou Biosciences Stock Is Crashing Today (Motley Fool) -30.47%
Mar-11-24 04:05PM	Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-05-24 04:30PM	Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Feb-26-24 01:14PM	12 $10 Stocks That Will Triple (Insider Monkey) +6.92%
06:45AM	Missed Out on CRISPR Therapeutics? My Best Gene-Editing Stock to Buy and Hold (Motley Fool)
Feb-23-24 11:25PM	Steven Cohen's Point72 Adds Caribou Biosciences Inc to Its Portfolio (GuruFocus.com)
Feb-15-24 04:05PM	Caribou Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-12-24 08:30AM	2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare (Motley Fool)
Jan-15-24 08:45AM	3 Biotech Stocks You Can Buy and Hold for the Next Decade (Motley Fool)
Jan-07-24 11:00AM	Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024 (GlobeNewswire)
Dec-13-23 07:26AM	5 Things to Know Before The Stock Market Opens (Investopedia)
05:20AM	3 Gene-Editing Stocks With the Potential to Mint Millionaires (InvestorPlace)
Dec-12-23 04:02PM	Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024 (GlobeNewswire)
Dec-08-23 12:00PM	Caribou Biosciences, Inc. (CRBU) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Dec-06-23 09:55AM	Wall Street Analysts Believe Caribou Biosciences, Inc. (CRBU) Could Rally 285.29%: Here's is How to Trade (Zacks)
Nov-20-23 09:55AM	Does Caribou Biosciences, Inc. (CRBU) Have the Potential to Rally 321.46% as Wall Street Analysts Expect? (Zacks) +6.51%
Nov-07-23 04:00PM	Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -5.03%
Nov-06-23 08:00AM	Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board (GlobeNewswire) +14.11%
Nov-01-23 04:05PM	Caribou Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-20-23 05:00AM	2 Top Growth Stocks to Buy Right Now Without Hesitation (Motley Fool)
Oct-18-23 08:00AM	Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (GlobeNewswire) -6.00%
Oct-11-23 06:00AM	2 Exciting Biotech Stocks to Buy With Less Than $10 (Motley Fool)
Oct-10-23 05:40AM	A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip (Motley Fool)
Oct-05-23 10:07AM	Avoid Big Losses With Biotech Stocks by Paying Attention to These 2 Things (Motley Fool)
Sep-27-23 08:30AM	2 Magnificent Growth Stocks to Buy On the Dip (Motley Fool)
08:00AM	Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer (GlobeNewswire)
Sep-23-23 08:45AM	1 Gene Editing Stock to Buy Now, and 1 to Sell (Motley Fool)
Aug-29-23 04:00PM	Caribou Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-24-23 05:58AM	3 Clever Tricks to Find Winning Biotech Stocks (Motley Fool)
Aug-15-23 04:08PM	Robert Bruce's Q2 2023 13F Filing Update: Key Trades and Portfolio Overview (GuruFocus.com)
03:08PM	Is Caribou Biosciences (CRBU) Stock Outpacing Its Medical Peers This Year? (Zacks)

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Haurwitz Rachel E.	President and CEO	Mar 14 '25	Buy	1.02	20,000	20,400	3,369,395	Mar 17 08:01 AM
MCCLUNG BARBARA G	Chief Legal Officer	Feb 21 '25	Sale	1.35	3,564	4,811	443,502	Feb 21 08:19 PM
Khan Ruhi Ahmad	Chief Business Officer	Feb 21 '25	Sale	1.35	3,564	4,811	66,936	Feb 21 08:19 PM
Kanner Steven	Chief Scientific Officer	Feb 21 '25	Sale	1.35	3,564	4,811	431,556	Feb 21 08:18 PM

Open in Screener

CDXS

Codexis Inc

Feb 13 • 04:00PM ET

1.20

+0.02 1.69 %

Healthcare • Biotechnology • USA • NASD

Peers: TSN DSM BIOX REGN INVA SGMO AVIR DVAX VNRX DTIL

| Held by: VTI IWM VXF IBB VTWO IWO FESM IWC IWN PRFZ

Index	RUT	P/E	-	EPS (ttm)	-0.75	Insider Own	3.05%	Shs Outstand	90.28M	Perf Week	-9.77%
Market Cap	108.39M	Forward P/E	-	EPS next Y	-0.40	Insider Trans	-33.09%	Shs Float	87.57M	Perf Month	-32.58%
Enterprise Value	117.82M	PEG	-	EPS next Q	-0.03	Inst Own	72.42%	Short Float	7.36%	Perf Quarter	-37.82%
Income	-63.95M	P/S	2.05	EPS this Y	28.09%	Inst Trans	-5.57%	Short Ratio	6.01	Perf Half Y	-61.29%
Sales	52.93M	P/B	2.81	EPS next Y	37.81%	ROA	-47.00%	Short Interest	6.45M	Perf YTD	-26.38%
Book/sh	0.43	P/C	1.83	EPS next 5Y	63.02%	ROE	-114.26%	52W High	4.46 -73.09%	Perf Year	-70.73%
Cash/sh	0.66	P/FCF	-	EPS past 3/5Y	-39.21% -33.31%	ROIC	-61.45%	52W Low	1.12 7.14%	Perf 3Y	-79.56%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-17.26% -2.82%	Gross Margin	69.97%	Volatility	7.83% 9.16%	Perf 5Y	-95.44%
Dividend TTM	-	EV/Sales	2.23	EPS Y/Y TTM	14.42%	Oper. Margin	-112.67%	ATR (14)	0.11	Perf 10Y	-70.44%
Dividend Ex-Date	-	Quick Ratio	4.02	Sales Y/Y TTM	-17.87%	Profit Margin	-120.82%	RSI (14)	35.87	Recom	1.57
Dividend Gr. 3/5Y	- -	Current Ratio	4.12	EPS Q/Q	24.15%	SMA20	-14.71%	Beta	2.47	Target Price	6.58
Payout	-	Debt/Eq	1.78	Sales Q/Q	-32.98%	SMA50	-24.14%	Rel Volume	1.29	Prev Close	1.18
Employees	188	LT Debt/Eq	1.70	Earnings	Nov 06 AMC	SMA200	-46.72%	Avg Volume	1.07M	Price	1.20
IPO	Apr 22, 2010	Option/Short	Yes / Yes	EPS/Sales Surpr.	-48.05% -53.54%	Trades		Volume	1,380,704	Change	1.69%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-19-24	Downgrade	The Benchmark Company	Buy → Hold
Jun-03-24	Resumed	Jefferies	Buy	$5
May-30-24	Initiated	Cantor Fitzgerald	Overweight	$11
Feb-29-24	Upgrade	The Benchmark Company	Hold → Buy
Nov-07-23	Downgrade	The Benchmark Company	Buy → Hold
Aug-07-23	Downgrade	TD Cowen	Outperform → Market Perform	$21 → $4
May-09-23	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-31-22	Resumed	Piper Sandler	Overweight	$35
Mar-02-22	Resumed	Cowen	Outperform
Apr-12-21	Initiated	Piper Sandler	Overweight	$32
Mar-01-21	Initiated	Stifel	Buy	$30
Feb-26-21	Reiterated	H.C. Wainwright	Buy	$21 → $26
Mar-10-20	Initiated	The Benchmark Company	Buy
Jan-17-19	Upgrade	First Analysis Sec	Neutral → Outperform	$12 → $19
May-16-18	Initiated	Stephens	Overweight	$16
Oct-13-17	Reiterated	H.C. Wainwright	Buy	$8 → $8.50
May-31-17	Initiated	Jefferies	Buy	$8
Jan-26-17	Downgrade	First Analysis Sec	Overweight → Equal-Weight	$5.50
Jan-04-17	Upgrade	Ladenburg Thalmann	Neutral → Buy
Jan-06-16	Initiated	H.C. Wainwright	Buy	$6

Show Previous Ratings

Feb-10-26 09:00AM	Codexis Achieves ISO 9001:2015 Certification (GlobeNewswire)
08:15AM	Incyte (INCY) Q4 Earnings Lag Estimates (Zacks)
Jan-07-26 09:00AM	Codexis Expands Reach of the ECO Synthesis Manufacturing Platform through a Signed Evaluation Agreement with Axolabs for Oligonucleotide Therapeutics (PR Newswire)
Nov-11-25 09:35AM	Down 30% in 4 Weeks, Here's Why You Should You Buy the Dip in Codexis (CDXS) (Zacks)
Nov-10-25 09:00AM	Codexis Announces Signing of Lease for GMP Manufacturing Facility (GlobeNewswire)
12:02AM	Loading…
Nov-07-25 12:02AM	Codexis Inc (CDXS) Q3 2025 Earnings Call Highlights: Strategic Shifts and New Partnerships ... (GuruFocus.com) -16.95%
Nov-06-25 08:00PM	Codexis (CDXS) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -5.35%
06:55PM	Codexis: Q3 Earnings Snapshot (Associated Press Finance)
04:21PM	Codexis Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-05-25 08:15AM	EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-04-25 05:55PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Oct-29-25 09:58AM	Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis Manufacturing Platform for Therapeutic siRNA Manufacturing (PR Newswire) -6.56%
Oct-23-25 07:05AM	Codexis to Report Third Quarter 2025 Financial Results on November 6 (GlobeNewswire)
Aug-28-25 09:00AM	Codexis to Participate in Cantor Global Healthcare Conference (GlobeNewswire)
Aug-14-25 03:12AM	Codexis Inc (CDXS) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic Growth Initiatives (GuruFocus.com)
05:15PM	Loading…
Aug-13-25 05:15PM	Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +6.64%
04:23PM	Codexis: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Codexis Reports Second Quarter 2025 Financial Results (GlobeNewswire)
07:30AM	[Latest] Global AI in Synthetic Biology Market Size/Share Worth USD 192.95 Billion by 2034 at a 28.63% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) (GlobeNewswire)
Aug-12-25 03:00PM	BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-11-25 08:10AM	Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-07-25 07:30AM	Switch Bioworks Expands Leadership Team and Moves into New Facility to Accelerate Development of its Microbial Fertilizer Products (PR Newswire)
Aug-04-25 05:15PM	Vertex Pharmaceuticals (VRTX) Surpasses Q2 Earnings and Revenue Estimates (Zacks) +5.58%
Aug-01-25 07:45AM	Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates (Zacks)
Jul-30-25 04:05PM	Codexis to Report Second Quarter 2025 Financial Results on August 13 (GlobeNewswire)
May-22-25 07:00AM	Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA (GlobeNewswire) +5.13%
May-21-25 04:05PM	Codexis to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-25 01:03PM	Q1 2025 Codexis Inc Earnings Call (Thomson Reuters StreetEvents)
03:15AM	Codexis Inc (CDXS) Q1 2025 Earnings Call Highlights: Navigating Revenue Volatility with ... (GuruFocus.com)
May-14-25 05:40PM	Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:39PM	Loading…
04:39PM	Codexis: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Codexis Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-13-25 05:10PM	Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-12-25 05:45PM	Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +7.32%
May-07-25 07:00AM	Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting (GlobeNewswire)
Apr-30-25 04:05PM	Codexis to Report First Quarter 2025 Financial Results on May 14 (GlobeNewswire)
Apr-24-25 10:01AM	Codexis (CDXS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:15AM	NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-09-25 05:00PM	Codexis Announces Byron Dorgan to Retire from Board of Directors (GlobeNewswire) +17.26%
Apr-03-25 10:01AM	Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last? (Zacks) -8.03%
Apr-01-25 07:00AM	Codexis Appoints Cynthia Collins to Board of Directors (GlobeNewswire) -6.69%
Mar-24-25 07:00AM	Codexis Announces First Revenue-Generating Contract for ECO Synthesis Manufacturing Services (GlobeNewswire) +20.39%
Mar-07-25 04:05PM	Codexis Announces New Employment Inducement Grants (GlobeNewswire) -6.74%
Feb-28-25 11:02AM	Q4 2024 Codexis Inc Earnings Call (Thomson Reuters StreetEvents) -22.65%
02:36AM	Codexis Inc (CDXS) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Revenue Growth ... (GuruFocus.com)
Feb-27-25 06:35PM	Codexis (CDXS) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -5.53%
05:36PM	Codexis: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Codexis Reports Fourth Quarter and Fiscal Year 2024 Financial Results (GlobeNewswire)
Feb-18-25 04:05PM	Codexis to Participate in TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-14-25 05:15PM	Codexis Announces New Employment Inducement Grants (GlobeNewswire) +5.12%
Feb-13-25 04:05PM	Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th (GlobeNewswire)
Feb-06-25 04:05PM	Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board (GlobeNewswire)
Jan-16-25 04:05PM	Codexis Appoints Christos Richards to Board of Directors (GlobeNewswire)
Jan-10-25 04:05PM	Codexis Announces New Employment Inducement Grants (GlobeNewswire) -7.77%
Dec-06-24 04:05PM	Codexis Announces New Employment Inducement Grants (GlobeNewswire) +15.22%
Nov-19-24 04:05PM	Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire) +8.14%
Nov-14-24 04:05PM	Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics (GlobeNewswire) -7.43%
Nov-12-24 04:05PM	Codexis Announces Appointment of Raymond De Vre, PhD, to Board of Directors (GlobeNewswire)
04:05PM	Codexis Announces Appointment of Raymond De Vr , PhD, to Board of Directors (GlobeNewswire)
Nov-11-24 04:05PM	Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics (GlobeNewswire)
Nov-08-24 04:05PM	Codexis Announces New Employment Inducement Grants (GlobeNewswire)
Nov-04-24 04:05PM	Codexis to Participate in Upcoming Healthcare Conferences (GlobeNewswire) +9.46%
Nov-01-24 09:01AM	Codexis Inc (CDXS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Focus ... (GuruFocus.com) +11.46%
Oct-31-24 05:30PM	Codexis (CDXS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:23PM	Codexis: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Codexis Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-24-24 04:05PM	Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting (GlobeNewswire)
Oct-22-24 04:05PM	Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors (GlobeNewswire) -7.27%
Oct-15-24 07:10AM	Codexis announces employment inducement grants (TipRanks) +5.28%
Oct-14-24 07:05AM	Codexis Announces New Employment Inducement Grants (GlobeNewswire)
Oct-10-24 04:05PM	Codexis to Report Third Quarter 2024 Financial Results on October 31 (GlobeNewswire) +6.06%
Oct-09-24 05:56PM	Codexis Inc (CDXS) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges and ... (GuruFocus.com)
Oct-02-24 04:05PM	Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company (GlobeNewswire)
Oct-01-24 07:05AM	Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences (GlobeNewswire)
Sep-26-24 01:01PM	Casdin Capital, LLC Increases Stake in Codexis Inc (GuruFocus.com) +6.53%
Sep-24-24 01:03AM	Opaleye Management Inc. Expands Stake in Codexis Inc. (GuruFocus.com)
Sep-20-24 02:25AM	Opaleye Management Inc. Increases Stake in Codexis Inc. (GuruFocus.com)
Sep-06-24 04:05PM	Codexis Announces New Employment Inducement Grants (GlobeNewswire)
Sep-03-24 04:05PM	Codexis to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Aug-20-24 04:05PM	Codexis to Participate in Enzymatic Synthesis Presentations at RNA Leaders Annual Meeting (GlobeNewswire)
Aug-16-24 04:05PM	Codexis Announces New Employment Inducement Grants (GlobeNewswire)
Aug-15-24 04:05PM	Codexis Publishes FY2023 Sustainability Disclosures (GlobeNewswire)
Aug-08-24 05:55PM	Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -11.11%
04:51PM	Codexis: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Codexis Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-18-24 04:05PM	Codexis to Report Second Quarter 2024 Financial Results on August 8 (GlobeNewswire) +7.58%
Jul-10-24 01:30PM	Crosswalk Therapeutics Announces Acquisition of Rare Disease Assets from Codexis, Inc. (PR Newswire)
Jul-03-24 07:37AM	Beacon raises $170M for eye gene therapy; J&J confirms Carvykti survival benefit (BioPharma Dive)
Jul-02-24 09:27AM	Crosswalk picks up Fabry, Pompe compounds from abandoned Takeda, Codexis collab (FierceBiotech.com)
Jul-01-24 04:05PM	Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets (GlobeNewswire)
Jun-12-24 05:48AM	Syntis Bio launches oral therapies for metabolic diseases (Pharmaceutical Technology)
May-22-24 04:25PM	Codexis to Participate in Jefferies Global Healthcare Conference (GlobeNewswire) -7.20%
May-20-24 04:05PM	Codexis to Participate in TD Cowen 2nd Annual Sustainability Week (GlobeNewswire) -5.82%
May-14-24 06:00AM	Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting (GlobeNewswire)
May-03-24 11:14AM	Codexis, Inc. (NASDAQ:CDXS) Q1 2024 Earnings Call Transcript (Insider Monkey) +17.37%
06:47AM	Q1 2024 Codexis Inc Earnings Call (Thomson Reuters StreetEvents)
04:01AM	Codexis Inc (CDXS) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-02-24 06:06PM	Codexis Inc (CDXS) Q1 2024 Earnings: Surpasses Revenue Forecasts with Strategic Advances (GuruFocus.com) +7.40%
05:34PM	Codexis: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Codexis Reports First Quarter 2024 Financial Results (GlobeNewswire)

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lutz Stefan	Chief Scientific Officer	Feb 06 '26	Sale	1.31	2,492	3,257	136,283	Feb 09 04:07 PM
Erbez Georgia	See Remarks	Feb 06 '26	Sale	1.31	3,826	5,001	66,810	Feb 09 04:07 PM
MOORE ALISON	President and CEO	Feb 06 '26	Sale	1.31	3,826	5,001	250,506	Feb 09 04:06 PM
Norrett Kevin	Officer	Feb 06 '26	Proposed Sale	1.27	3,291	4,180		Feb 06 06:18 PM
Lutz Stefan	Officer	Feb 06 '26	Proposed Sale	1.27	2,460	3,124		Feb 06 06:15 PM
KEVIN NORRETT	Officer	Jan 16 '26	Proposed Sale	1.67	1,745	2,914		Jan 16 05:09 PM
Lutz Stefan	CSO	Jan 07 '26	Sale	1.70	4,685	7,950	138,775	Jan 08 06:51 PM
Norrett Kevin	Officer	Jan 07 '26	Proposed Sale	1.70	6,123	10,409		Jan 07 09:17 PM
Opaleye Management Inc.	10% Owner	Dec 01 '25	Sale	1.67	253,533	422,766	179,989	Dec 01 05:41 PM
Opaleye Management Inc.	10% Owner	Nov 28 '25	Sale	1.75	107,490	188,108	188,522	Dec 01 05:41 PM
Opaleye Management Inc.	10% Owner	Nov 26 '25	Sale	1.74	5,000	8,706	191,012	Dec 01 05:41 PM
WOLF DENNIS P	Director	Nov 21 '25	Sale	1.56	8,952	13,988	138,951	Nov 25 04:18 PM
DENNIS P WOLF	Officer	Nov 21 '25	Proposed Sale	1.56	8,952	13,988		Nov 21 04:51 PM
Opaleye Management Inc.	10% Owner	Nov 12 '25	Sale	1.96	192,459	376,924	196,012	Nov 14 04:15 PM
De Vre Raymond	Director	Nov 11 '25	Sale	1.74	1,413	2,459	87,416	Nov 13 04:16 PM
Opaleye Management Inc.	10% Owner	Nov 11 '25	Sale	1.80	548,211	986,451	223,461	Nov 12 04:05 PM
Opaleye Management Inc.	10% Owner	Nov 10 '25	Sale	1.73	208,318	361,369	236,682	Nov 12 04:05 PM
Opaleye Management Inc.	10% Owner	Nov 07 '25	Sale	1.70	10,000	16,968	240,000	Nov 12 04:05 PM
MOORE ALISON	Chief Technical Officer	Oct 13 '25	Sale	2.51	6,239	15,629	169,332	Oct 15 05:14 PM
Erbez Georgia	Chief Financial Officer	Oct 13 '25	Sale	2.50	6,239	15,629	70,636	Oct 15 05:13 PM
Erbez Georgia	Officer	Oct 13 '25	Proposed Sale	2.51	6,239	15,629		Oct 14 05:08 PM
MOORE ALISON	Officer	Oct 13 '25	Proposed Sale	2.51	6,239	15,630		Oct 14 05:00 PM
Opaleye Management Inc.	10% Owner	Jul 31 '25	Buy	2.68	84,220	225,710	12,544,220	Aug 04 04:38 PM
Opaleye Management Inc.	10% Owner	Aug 04 '25	Buy	2.83	780	2,211	12,545,000	Aug 04 04:38 PM
Opaleye Management Inc.	10% Owner	Jul 29 '25	Buy	2.82	8,422	23,750	12,458,422	Jul 31 04:05 PM
Opaleye Management Inc.	10% Owner	Jul 30 '25	Buy	2.79	1,578	4,411	12,460,000	Jul 31 04:05 PM
Opaleye Management Inc.	10% Owner	Jul 18 '25	Buy	2.82	100,000	282,000	12,450,000	Jul 22 04:05 PM
Opaleye Management Inc.	10% Owner	Jun 27 '25	Buy	2.39	100,000	239,000	12,350,000	Jul 01 04:05 PM
Opaleye Management Inc.	10% Owner	Jun 12 '25	Buy	2.25	100,000	225,000	12,100,000	Jun 16 04:59 PM
Opaleye Management Inc.	10% Owner	Jun 13 '25	Buy	2.23	99,102	220,997	12,199,102	Jun 16 04:59 PM
Opaleye Management Inc.	10% Owner	Jun 16 '25	Buy	2.24	50,898	114,012	12,250,000	Jun 16 04:59 PM
Opaleye Management Inc.	10% Owner	May 23 '25	Buy	2.36	2,320,000	5,475,200	11,995,000	May 28 04:05 PM
Opaleye Management Inc.	10% Owner	May 28 '25	Buy	2.36	5,000	11,800	12,000,000	May 28 04:05 PM
Opaleye Management Inc.	10% Owner	Apr 30 '25	Buy	2.31	25,000	57,660	9,655,000	May 02 04:05 PM
Opaleye Management Inc.	10% Owner	May 01 '25	Buy	2.32	20,000	46,436	9,675,000	May 02 04:05 PM
Opaleye Management Inc.	10% Owner	Apr 25 '25	Buy	2.24	25,000	55,915	9,630,000	Apr 29 04:05 PM
Opaleye Management Inc.	10% Owner	Apr 16 '25	Buy	2.13	70,000	148,890	9,560,000	Apr 17 06:07 PM
Opaleye Management Inc.	10% Owner	Apr 17 '25	Buy	2.09	45,000	94,162	9,605,000	Apr 17 06:07 PM
Opaleye Management Inc.	10% Owner	Apr 15 '25	Buy	2.23	25,000	55,720	9,490,000	Apr 17 06:07 PM
Opaleye Management Inc.	10% Owner	Apr 08 '25	Buy	1.98	100,000	198,380	9,465,000	Apr 09 04:05 PM
Opaleye Management Inc.	10% Owner	Apr 03 '25	Buy	2.30	75,000	172,740	9,365,000	Apr 03 07:39 PM
Opaleye Management Inc.	10% Owner	Apr 01 '25	Buy	2.48	35,000	86,772	9,285,000	Apr 03 07:39 PM
Opaleye Management Inc.	10% Owner	Apr 02 '25	Buy	2.46	5,000	12,276	9,290,000	Apr 03 07:39 PM
Opaleye Management Inc.	10% Owner	Mar 21 '25	Buy	2.54	92,923	236,266	9,250,000	Mar 24 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 20 '25	Buy	2.54	7	18	9,157,077	Mar 24 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 13 '25	Buy	2.54	85,000	216,155	9,150,000	Mar 14 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 06 '25	Buy	2.61	100,000	261,350	9,065,000	Mar 10 05:16 PM
Opaleye Management Inc.	10% Owner	Mar 04 '25	Buy	2.64	55,000	145,398	8,955,000	Mar 06 04:51 PM
Opaleye Management Inc.	10% Owner	Mar 05 '25	Buy	2.69	10,000	26,875	8,965,000	Mar 06 04:51 PM
Opaleye Management Inc.	10% Owner	Feb 28 '25	Buy	2.99	147,649	441,175	8,852,649	Mar 04 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 03 '25	Buy	2.81	47,351	133,165	8,900,000	Mar 04 04:05 PM

CRBU

Caribou Biosciences Inc

CDXS

Codexis Inc

Upgrade your FINVIZ experience